{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:50:09Z","timestamp":1792533009808,"version":"4.5.0"},"reference-count":40,"publisher":"Radcliffe Medical Media Ltd","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>There has been a great evolution in the development of coronary stents in order to avoid both restenosis and thrombosis. Improvements have led to improvements in the design and conformation of metallic or resorbable structures, with an adequate balance between trackability and radial force, the development of antiproliferative drugs and the polymers to control release and allow adequate endothelialisation and an optimal duration of the antiplatelet regimen. Some suggestions are provided about the ideal characteristics of future coronary stents.<\/jats:p>","DOI":"10.15420\/ecr.2018:8:2","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T12:01:32Z","timestamp":1535025692000},"page":"54","source":"Crossref","is-referenced-by-count":142,"title":["The Newest Generation of Drug-eluting Stents and Beyond"],"prefix":"10.15420","volume":"13","author":[{"given":"Dae-Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cardiology Service, Interventional Cardiology Unit, University Hospital Marques de Valdecilla, Santander, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M de la","family":"Torre Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Cardiology Service, Interventional Cardiology Unit, University Hospital Marques de Valdecilla, Santander, Spain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4244\/EIJ-D-17-00557","article-title":"State of the art: coronary artery stents - past, present and future","volume":"13","author":"Stefanini","year":"2017","unstructured":"1. Stefanini GG, Byrne RA, Windecker S, Kastrati A. State of the art: coronary artery stents - past, present and future. EuroIntervention 2017;13:706-16.","journal-title":"EuroIntervention"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/ica.13.84","article-title":"Optimal stent design: past, present and future","volume":"6","author":"Karjalainen","year":"2014","unstructured":"2. Karjalainen PP, Nammas W, Airaksinen J. Optimal stent design: past, present and future. Interv Cardiol 2014;6:29-44.","journal-title":"Interv Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1615\/JLongTermEffMedImplants.v10.i12.120","article-title":"Influence of topography on endothelization of stents: clues for new designs","volume":"10","author":"Simon","year":"2000","unstructured":"3. Simon C, Palmaz JC, Sprague EA. Influence of topography on endothelization of stents: clues for new designs. J Long Term Eff Med Implant 2000;10:143-51.","journal-title":"J Long Term Eff Med Implant"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1161\/01.CIR.103.23.2816","article-title":"Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial","volume":"103","author":"Kastrati","year":"2001","unstructured":"4. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21.","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/136457002760273340","article-title":"A survey of stent designs","volume":"11","author":"Stoeckel","year":"2002","unstructured":"5. Stoeckel D, Bonsignore C, Duda S. A survey of stent designs. Min Invas Ther Allied Technol 2002;11:137-47.","journal-title":"Min Invas Ther Allied Technol"},{"key":"ref5","unstructured":"6. Wholey M, Finol E. Designing the ideal stent. Endovascular Today 2007;6:25-34."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/01.CIR.104.8.852","article-title":"Bench to bedside: the development of rapamycin and its application in stent restenosis","volume":"104","author":"SO","year":"2001","unstructured":"7. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application in stent restenosis. Circulation 2001;104:852-5.","journal-title":"Circulation"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(07)61444-5","article-title":"Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis","volume":"370","author":"Stettler","year":"2007","unstructured":"8. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jacc.2007.06.047","article-title":"A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease","volume":"50","author":"Schomig","year":"2007","unstructured":"9. Schomig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1373-80.","journal-title":"J Am Coll Cardiol"},{"key":"ref9","unstructured":"10. Xue L, Sharma R, Cochran K. Effects of rapamycin derivative ABT-578 on canine smooth muscle cells and endothelial cell proliferation. Preclinica 2004;2:451-5."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1517\/14740338.2015.1040388","article-title":"Everolimus and sirolimus in transplantation - related but different","volume":"14","author":"Klawitter","year":"2015","unstructured":"11. Klawitter J, Nashan B, Christians U. Everolimus and sirolimus in transplantation - related but different. Expert Opin Drug Saf 2015;14:1055-70.","journal-title":"Expert Opin Drug Saf"},{"key":"ref11","unstructured":"12. Grube E, Buellesfeld L. Everolimus for stent-based intracoronary applications. Rev Cardiovasc Med 2004;5:S3-8."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.amjcard.2006.02.051","article-title":"Angiographic results of the first human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions","volume":"98","author":"Costa","year":"2006","unstructured":"13. Costa R, Lansky A, Abizaid A. Angiographic results of the first human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 2006;98:443-6.","journal-title":"Am J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Abizaid A, Costa JR Jr, Feres F. TCT-429: Single center, first-in-man study of the elixir novolimus eluting coronary stent system with durable polymer 24-month clinical safety and efficacy results. Am J Cardiol 2009;104:158D.","DOI":"10.1016\/j.amjcard.2009.08.454"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202. https:\/\/doi.org\/10.1016\/j.jacc.2006.03.042; PMID: 16814667.","DOI":"10.1016\/j.jacc.2006.03.042"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ijpharm.2012.10.029","article-title":"Recent advances in drug eluting stents","volume":"441","author":"Puranik","year":"2013","unstructured":"16. Puranik AS, Dawson ER, Peppas NA. Recent advances in drug eluting stents. Int J Pharm 2013;441:665-79.","journal-title":"Int J Pharm"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Serra A, Miranda F, Venegas R. An\u00e1lisis y caracter\u00edsticas de los stents farmacoactivos disponibles en la actualidad. Futuros desarrollos. Rev Esp Cardiol Suplementos 2007;7:8E-28 [in Spanish].","DOI":"10.1016\/S1131-3587(07)75778-3"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17434440.2017.1363646","article-title":"Clinical implications of blood-material interaction and drug eluting stent polymers in review","volume":"14","author":"Mori","year":"2017","unstructured":"18. Mori H, Gupta A, Torii S, et al. Clinical implications of blood-material interaction and drug eluting stent polymers in review. Expert Rev Med Devices 2017;14:707-16.","journal-title":"Expert Rev Med Devices"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"029806","DOI":"10.1116\/1.4944586","article-title":"Blood compatibility assessment of polymers used in drug eluting stent coatings","volume":"11","author":"Szott","year":"2016","unstructured":"19. Szott LM, Irvin CA, Trollsas M, et al. Blood compatibility assessment of polymers used in drug eluting stent coatings. Biointerphases 2016;11:029806.","journal-title":"Biointerphases"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcin.2016.11.007","article-title":"Comparison of durable-polymer zotarolimus-eluting and biodegradable-polymer biolimus-eluting coronary stents in patients with coronary artery disease: 3-year clinical 0utcomes in the randomized SORT OUT VI trial","volume":"10","author":"Raungaard","year":"2017","unstructured":"20. Raungaard B, Christiansen EH, B\u00f8tker HE, et al. Comparison of durable-polymer zotarolimus-eluting and biodegradable-polymer biolimus-eluting coronary stents in patients with coronary artery disease: 3-year clinical 0utcomes in the randomized SORT OUT VI trial. JACC Cardiovasc Interv 2017;10:255-64.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.jcin.2008.11.015","article-title":"Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer","volume":"2","author":"Byrne","year":"2009","unstructured":"21. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.recesp.2012.12.009","article-title":"Progress in treatment by percutaneous coronary intervention: the stent of the future","volume":"66","author":"Muramatsu","year":"2013","unstructured":"22. Muramatsu T, Onuma Y, Zhang YJ, et al. Progress in treatment by percutaneous coronary intervention: the stent of the future. Rev Esp Cardiol (Engl Ed) 2013;66:483-96","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11883-017-0654-1","article-title":"New-generation coronary stents: current data and future directions","volume":"19","author":"Kalra","year":"2017","unstructured":"23. Kalra A, Rehman H, Khera S, et al. New-generation coronary stents: current data and future directions. Curr Atheroscler Rep 2017;19:14.","journal-title":"Curr Atheroscler Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cpcardiol.2017.04.001","article-title":"Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"42","author":"Sharma","year":"2017","unstructured":"24. Sharma A, Hai O, Garg A, et al. Duration of dual antiplatelet therapy following drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 2017;42:404-17.","journal-title":"Curr Probl Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jcin.2015.09.008","article-title":"Polymer-free biolimus A9-coated stents in the treatment of de novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter BioFreedom FIM clinical trial","volume":"9","author":"Costa","year":"2016","unstructured":"25. Costa RA, Abizaid A, Mehran R, et al. Polymer-free biolimus A9-coated stents in the treatment of de novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter BioFreedom FIM clinical trial. JACC Cardiovasc Interv 2016;9: 51-64.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.actbio.2015.02.006","article-title":"Some design considerations for polymer-free drug-eluting stents: a mathematical approach","volume":"18","author":"McGinty","year":"2015","unstructured":"26. McGinty S, Vo TT, Meere M, et al. Some design considerations for polymer-free drug-eluting stents: a mathematical approach. Acta Biomater 2015;18:213-25.","journal-title":"Acta Biomater"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jcin.2016.10.020","article-title":"First-in-human evaluation of a novel polymer-free drug-filled stent: angiographic, IVUS, OCT, and clinical outcomes from the RevElution study","volume":"10","author":"Worthley","year":"2017","unstructured":"27. Worthley SG, Abizaid A, Kirtane AJ, et al. First-in-human evaluation of a novel polymer-free drug-filled stent: angiographic, IVUS, OCT, and clinical outcomes from the RevElution study. JACC Cardiovasc Interv 2017;10:147-56.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4244\/EIJV4I4A85","article-title":"Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PRO-Kinetic enhancing rapid in-stent endothelialisation)","volume":"4","author":"JB1","year":"2009","unstructured":"28. Dahm JB1, Willems T, Wolpers HG, et al. Clinical investigation into the observation that silicon carbide coating on cobalt chromium stents leads to early differentiating functional endothelial layer, increased safety and DES-like recurrent stenosis rates: results of the PRO-Heal Registry (PRO-Kinetic enhancing rapid in-stent endothelialisation). EuroIntervention 2009;4:502-8.","journal-title":"EuroIntervention"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ijcard.2010.01.009","article-title":"The CID Chrono cobalt-chromium alloy carbofilm-coated coronary stent system","volume":"149","author":"Visconti","year":"2011","unstructured":"29. Visconti G, Focaccio A, Tavano D, et al. The CID Chrono cobalt-chromium alloy carbofilm-coated coronary stent system. Int J Cardiol 2011;149:199-204.","journal-title":"Int J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcin.2009.09.015","article-title":"Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization","volume":"3","author":"Nakazawa","year":"2010","unstructured":"30. Nakazawa G, Granada JF, Alviar CL, et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 2010;3:68-75.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1080\/07853890.2016.1244353","article-title":"Titanium-nitride-oxide-coated coronary stents: insights from the available evidence","volume":"49","author":"PP","year":"2017","unstructured":"31. Karjalainen PP, Nammas W. Titanium-nitride-oxide-coated coronary stents: insights from the available evidence. Ann Med 2017;49:299-309.","journal-title":"Ann Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2217\/nnm.16.3","article-title":"Nanotechnology in diagnosis and treatment of coronary artery disease","volume":"11","author":"Karimi","year":"2016","unstructured":"32. Karimi M, Zare H, Bakhshian Nik A, et al. Nanotechnology in diagnosis and treatment of coronary artery disease. Nanomedicine (Lond) 2016;11:513-30.","journal-title":"Nanomedicine (Lond)"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Wykrzykowska JJ, Onuma Y, Serruys PW. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate \"rosy\" prophecy. EuroIntervention 2009;5:F7-8.","DOI":"10.4244\/EIJV5IFA1"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ijcard.2017.05.087","article-title":"Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100","volume":"246","author":"Boeder","year":"2017","unstructured":"34. Boeder NF, D\u00f6rr O, Bauer T, et al. Impact of strut thickness on acute mechanical performance: A comparison study using optical coherence tomography between DESolve 150 and DESolve 100. Int J Cardiol 2017;246:74-9.","journal-title":"Int J Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jcin.2015.10.019","article-title":"Collapse of a bioresorbable novolimus-eluting coronary scaffold","volume":"9","author":"Braun","year":"2016","unstructured":"35. Braun D, Baquet M, Massberg S, et al. Collapse of a bioresorbable novolimus-eluting coronary scaffold. JACC Cardiovasc Interv 2016;9:13-4.","journal-title":"JACC Cardiovasc Interv"},{"key":"ref35","unstructured":"36. Ruiz-Salmer\u00f3n RJ, Pereira S, de Araujo D. Bioresorbable vascular scaffold collapse causes subacute thrombosis. J Invasive Cardiol 2014;26:98-9."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/j.jacc.2017.04.011","article-title":"Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents","volume":"69","author":"Sorrentino","year":"2017","unstructured":"37. Sorrentino S, Giustino G, Mehran R, et al. Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. J Am Coll Cardiol 2017;69:3055-66.","journal-title":"J Am Coll Cardiol"},{"key":"ref37","unstructured":"38. Thakkar AS, Dave BA. Revolution of drug-eluting coronary stents: an analysis of market leaders. Eur Med J 2016; 4:114-25."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","unstructured":"39. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-60.","journal-title":"Eur Heart J"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.jacc.2016.10.009","article-title":"2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents","volume":"69","author":"Garot","year":"2017","unstructured":"40. Garot P, Morice MC, Tresukosol D, et al. 2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents. J Am Coll Cardiol 2017;69:162-71.","journal-title":"J Am Coll Cardiol"}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articles\/drug-eluting-stents-and-beyond","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T11:28:44Z","timestamp":1599564524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articles\/drug-eluting-stents-and-beyond"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"alternative-id":["ecr.2018:8:2"],"URL":"https:\/\/doi.org\/10.15420\/ecr.2018:8:2","relation":{},"ISSN":["1758-3756"],"issn-type":[{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}